RGD-Modified Polypeptide Antiangiogenesis Agent
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenesis drugs like endostatin and angiostatin lack specificity and selectivity, requiring high doses that increase side effects, production costs, and complexity, necessitating a more targeted and efficient approach to inhibit tumor growth and metastasis.
Innovation Solution
Development of a highly efficient antiangiogenesis agent with binding affinity to integrin, achieved by modifying polypeptides with sequences containing arginine-glycine-aspartic acid (RGD) at both ends, synthesized using prokaryotic or eukaryotic expression vectors, and further enhanced through physiochemical modifications such as PEGylation, to create nano-drugs like polylactic acid or poly-butylcyanoacrylate particles for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of angiostatin or endostatin are used to inhibit angiogenesis, then the inhibitory effect is achieved, but side effects increase and production costs rise
Solution Approach 1:
The patent applies local quality by modifying the polypeptide structure to include RGD sequences at specific locations (N-terminal and/or C-terminal) that provide targeted binding to integrin receptors on endothelial cells. This localized modification creates high-affinity binding sites that concentrate the drug's effect at the target site, enabling effective angiogenesis inhibition at much lower doses (picomolar to nanomolar range) compared to unmodified angiostatin or endostatin, thereby reducing systemic side effects
Solution Approach 2:
The patent changes the biochemical parameters of the drug by incorporating RGD sequences that specifically recognize integrin receptors. This parameter change (adding specific amino acid sequences) fundamentally alters the drug-receptor interaction, creating high-affinity binding that increases potency by several orders of magnitude, allowing effective treatment at doses that minimize side effects
2Reliability
If high doses of angiostatin or endostatin are used to inhibit angiogenesis, then the inhibitory effect is achieved, but production costs and drug prices increase
Solution Approach 1:
The patent applies local quality by modifying the polypeptide structure to include RGD sequences at specific locations (N-terminal and/or C-terminal) that provide targeted binding to integrin receptors on endothelial cells. This localized modification creates high-affinity binding sites that concentrate the drug's effect at the target site, enabling effective angiogenesis inhibition at much lower doses (picomolar to nanomolar range) compared to unmodified angiostatin or endostatin, thereby reducing systemic side effects
Solution Approach 2:
The patent changes the biochemical parameters of the drug by incorporating RGD sequences that specifically recognize integrin receptors. This parameter change (adding specific amino acid sequences) fundamentally alters the drug-receptor interaction, creating high-affinity binding that increases potency by several orders of magnitude, allowing effective treatment at doses that minimize side effects
3Reliability
If RGD sequences are added to polypeptides to enhance binding affinity to integrin, then selectivity and potency increase, but molecular complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the polypeptide into functional domains: the core angiogenesis-inhibiting domain (from angiostatin or endostatin) and the targeting domain (RGD sequences). This segmentation allows the RGD moieties to be added as discrete functional units at the N-terminal, C-terminal, or both ends of the polypeptide, creating a modular structure that enhances selectivity without completely redesigning the entire molecule
Solution Approach 2:
The patent applies universality by using the RGD sequence, a well-known cell-adhesion motif, as a universal targeting element that can be attached to various angiogenesis-inhibiting polypeptides. This universal approach allows the same RGD modification strategy to be applied across different polypeptide backbones, creating multi-functional molecules that combine targeting capability with angiogenesis inhibition
4Device complexity
If short peptides are used to inhibit angiogenesis, then the structure is simple, but the half-life and stability are insufficient
Solution Approach 1:
The patent applies composite materials by creating chimeric polypeptides that combine the angiogenesis-inhibiting core (from angiostatin or endostatin) with RGD targeting sequences. This composite structure integrates two functional elements into a single molecule, where the RGD portion provides targeting and the core provides inhibition, resulting in a unified agent with improved pharmacokinetic properties including extended half-life and enhanced stability compared to short peptides alone
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified RGD-containing polypeptides demonstrate significant endothelial cell proliferation inhibition and anti-tumor effects at low doses, reducing side effects and production costs, while extending half-life and stability, thus enhancing clinical efficacy and application scope.
Implementation Method 1
different sequences containing arginine - glycine - aspartic amino acid are added to both ends of the small polypeptides that inhibit angiogenesis to construct a kind of antiangiogenesis agent having binding effect and affinity with the integrin
Implementation Method 2
Physiochemical modification is an important process to enhance the effectiveness of polypeptides or proteins in the treatment or biotechnology
Implementation Method 3
The PEG-polypeptide s (or PEG-protein) products currently available on the markets include many varieties
Data Source
Figure 1~2D
Figure 3~4
AI summary
The present invention relates to a highly efficient antiangiogenesis agent, which is a polypeptide for inhibition of angiogenesis Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, connected with a polypeptide containing Arg-Gly-Asp on its one end or two ends. The inhibiting agent can be synthesized or gene engineered. The invention also relates to a physiochemical method for modifying the antiangiogenesis agent. Polypeptides with weight percentage of 1-70% preferably about 20-50% are mixed with 20%-95% polyethylene glycol, or heparin, or dextran, or polyvinylpyrrolidone, or polyethylene glycol - poly-amino acid copolymer, or palmitic acid or poly-sialic acid or liposomes solutions; preferably about 50-93% of the above modified substances are fully mixed even and shaken at a shaker at 4°C -40°C, preferably 25°C -37°C for more than 10 min, and the modified substances are separated through appropriate methods. The invention still relates to the use of the above polypeptides and the polypeptide modified substances for manufacturing medicaments for treating human solid tumors.